Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc., USA. The transaction received approval from the U.S. Federal Trade Commission on June 18, 2026, concluding the purchase from Lannett Seller Holdco, Inc.

Effective June 29, 2026, Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc and will operate as Lannett Company LLC. The integration process has commenced immediately, with a focus on ensuring uninterrupted access to critical medications and maintaining relationships with partners.

The acquisition adds more than 400 Lannett employees to the organization, strengthening its talent base and operational capabilities. The company aims to combine resources to enhance the availability of essential medicines and deliver long-term value to patients and stakeholders.

Aurobindo Pharma Limited acknowledged the leadership of Lannett's management team for their role in enabling a smooth transition. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Key Transaction Timeline

The following table outlines the key milestones in the completion of the acquisition:

Aurobindo Pharma recently underwent a US Food and Drug Administration (FDA) inspection at one of its facilities, which concluded with two observations recorded by the regulatory authority. As per standard regulatory protocol, the company is required to submit its response to the observations within the stipulated timeframe.

US FDA Inspection Outcome

The US FDA inspection of the Aurobindo Pharma facility has been completed, with the regulatory body noting two observations at the conclusion of the inspection process. Such observations, commonly documented on a Form 483, are a standard part of the US FDA's inspection procedure for pharmaceutical manufacturing sites.

Key Details of the Inspection

Response and Next Steps

Aurobindo Pharma is expected to file its response to the two observations within the required timeframe as mandated by the US FDA. The submission of a timely and comprehensive response is a standard regulatory requirement following the conclusion of any FDA inspection that results in observations. The outcome of the inspection and the company's subsequent response will be subject to further review by the regulatory authority.